PsyWire

Culture

The A-Strain Mushroom — All You Need to Know

AI summary

The A-Strain mushroom, a high-potency psilocybin variant, is gaining attention for its consistent chemical profile and potential therapeutic applications, positioning it as a key player in the expanding psychedelic industry. Tripsitter’s analysis underscores its role in both recreational and research contexts, highlighting its cultivation challenges and market demand. As interest in psychedelic-assisted therapies grows, the A-Strain’s unique properties may influence future regulatory and commercial developments.

Tripsitter · Mon, 29 Aug 2022 13:23:40 +0000

Culture

Alcabenzi Magic Mushroom Strain: Mild, Euphoric & Insightful

AI summary

The Alcabenzi Magic Mushroom Strain, featured in Tripsitter's article, is noted for its mild potency, euphoric effects, and insightful experiences, making it a popular choice for those seeking a balanced psychedelic journey. As a hybrid strain, it combines the traits of its parent varieties to deliver a gentle yet meaningful psychedelic experience. Its accessibility and therapeutic potential have positioned it as a notable addition to the emerging psychedelic market.

Tripsitter · Mon, 29 Aug 2022 13:40:26 +0000

Culture

Giant Jungle Shrooms: Exploring The Amazon Mushroom Strain

AI summary

The article explores the Amazon mushroom strain, known for its large size and potent psychoactive properties, highlighting its traditional use by indigenous communities and growing interest in the psychedelic industry for its unique effects and potential therapeutic applications. Researchers and enthusiasts are increasingly studying its chemical composition and cultural significance, positioning it as a notable player in the expanding psychedelic market.

Tripsitter · Mon, 29 Aug 2022 13:53:36 +0000

Culture

Gold Coast Strain: What Makes It Special?

AI summary

The Gold Coast Strain, highlighted in Tripsitter's article, is distinguished by its unique combination of potency, flavor profile, and therapeutic potential, making it a notable cultivar in the psychedelic industry. Researchers and users note its balanced effects, which may offer relief for anxiety and pain while maintaining a clear-headed experience. Its growing popularity underscores its significance as a versatile option for both recreational and medicinal applications.

Tripsitter · Mon, 29 Aug 2022 14:08:50 +0000

Culture

Burma Cubensis: Everything You Need to Know About This Powerful Magic Mushroom

AI summary

Burma Cubensis, a potent and sought-after magic mushroom strain originating from Southeast Asia, is noted for its high psilocybin content and intense, immersive psychedelic experience. The article highlights its potential for deep emotional exploration and therapeutic applications, though its legal status remains complex in many regions. As interest in psychedelic research grows, Burma Cubensis is increasingly recognized as a significant player in the evolving psychedelic industry.

Tripsitter · Mon, 29 Aug 2022 14:21:47 +0000

Culture

Rick Doblin, Ph.D: Founder & Executive Director of MAPS

AI summary

Rick Doblin, Ph.D., founder and executive director of MAPS, is a leading advocate for psychedelic research, focusing on the therapeutic potential of substances like MDMA and psilocybin. His work emphasizes advancing clinical trials, policy reform, and public education to integrate psychedelics into mainstream mental health treatment. Doblin’s background as a psychologist and his decades-long commitment to decriminalization and scientific rigor have positioned him as a pivotal figure in the psychedelic renaissance.

Tripsitter · Tue, 30 Aug 2022 17:33:17 +0000

Culture

Can Microdosing Psychedelics Help With ADHD?

AI summary

A growing body of research suggests microdosing psychedelics like psilocybin or LSD may offer potential benefits for ADHD symptoms, including enhanced focus and reduced hyperactivity, though more rigorous clinical trials are needed to confirm efficacy and safety. The Tripsitter article highlights emerging evidence and calls for further investigation into psychedelic-assisted therapies as a complementary approach for ADHD management. Researchers caution against self-medication and emphasize the importance of professional guidance in exploring these treatments.

Tripsitter · Tue, 30 Aug 2022 20:47:13 +0000

Culture

Where to Buy Magic Mushroom Spores in Denmark

AI summary

The article from Tripsitter outlines the legal and practical challenges of purchasing magic mushroom spores in Denmark, where psychedelic substances are strictly regulated. It highlights the prevalence of underground markets and online vendors, though warns of risks including legal repercussions and inconsistent product quality. The piece underscores the broader implications for psychedelic research and cultural attitudes toward psychedelics in the region.

Tripsitter · Thu, 01 Sep 2022 09:20:58 +0000

Culture

Where to Buy Magic Mushroom Spores in France

AI summary

The article from Tripsitter outlines the legal and practical challenges of purchasing magic mushroom spores in France, where psilocybin-containing substances are strictly prohibited. It highlights the risks of underground markets and the potential for legal repercussions, emphasizing the importance of compliance with French drug laws. The piece serves as a cautionary guide for individuals seeking to engage with psychedelics in a regulated context.

Tripsitter · Thu, 01 Sep 2022 09:43:25 +0000

Policy

Correcting the Record: What The New York Times Got Wrong

AI summary

Psymposia's article "Correcting the Record: What The New York Times Got Wrong" addresses inaccuracies in a recent New York Times piece about psychedelics, clarifying key scientific and therapeutic aspects of the field. The piece highlights misrepresentations regarding research findings, regulatory progress, and clinical applications, emphasizing the need for factual precision in media coverage. These corrections underscore the importance of accurate reporting to support the growing legitimacy and potential of psychedelic medicine.

Psymposia · Fri, 07 Mar 2025 17:29:11 +0000

Policy

Correcting the Record: Addressing The New York Times’ Deceptive Coverage of Psymposia

AI summary

Psymposia has issued a rebuttal to The New York Times’ recent coverage, asserting that the publication misrepresented key aspects of the organization’s work and advocacy for psychedelic research. The article highlights alleged inaccuracies in the Times’ reporting, which Psymposia claims downplays its role in advancing therapeutic applications and regulatory progress. The response underscores the importance of factual transparency in shaping public understanding of the psychedelic industry.

Psymposia · Fri, 07 Mar 2025 17:31:03 +0000

Policy

The Psychedelic Syndicate: Part 1

AI summary

"The Psychedelic Syndicate: Part 1" from Psymposia explores the emergence of a collaborative network uniting researchers, clinicians, and entrepreneurs to advance psychedelic science and therapy. The article highlights efforts to standardize clinical protocols, navigate regulatory challenges, and expand access to psychedelic-assisted treatments. It underscores the growing industry focus on evidence-based innovation and its potential to reshape mental health care.

Psymposia · Fri, 10 Oct 2025 16:54:37 +0000

Policy

The Psychedelic Syndicate: Part 2

AI summary

"The Psychedelic Syndicate: Part 2" from Psymposia explores the evolving role of collaborative networks in the psychedelic industry, highlighting their impact on regulatory navigation, market expansion, and stakeholder engagement. The article underscores challenges such as legal ambiguities and operational scalability, while emphasizing the potential for structured alliances to drive innovation and compliance. It positions these syndicates as pivotal players in shaping the industry’s future amid growing mainstream interest.

Psymposia · Fri, 10 Oct 2025 16:56:17 +0000

Policy

The Psychedelic Syndicate: Part 3

AI summary

"The Psychedelic Syndicate: Part 3" explores the rapid expansion of the psychedelic industry, highlighting key players, regulatory challenges, and emerging collaborations shaping the market's trajectory. The article emphasizes the growing influence of corporate and institutional stakeholders in advancing therapeutic applications and scaling psychedelic therapies. It underscores the industry's evolving landscape as it navigates legal, ethical, and commercial complexities.

Psymposia · Fri, 10 Oct 2025 16:57:02 +0000

Policy

The Psychedelic Syndicate: Part 4

AI summary

"The Psychedelic Syndicate: Part 4" from Psymposia explores the evolving regulatory and market dynamics within the psychedelic industry, highlighting key collaborations between biotech firms and advocacy groups to navigate federal policies and expand therapeutic applications. The article emphasizes growing investor interest and the push for standardized clinical trials, signaling a maturing sector poised for significant growth. It also addresses ongoing challenges in balancing innovation with public safety concerns.

Psymposia · Fri, 10 Oct 2025 16:57:44 +0000

Policy

Hamilton’s Pharma Cope, Part 1: “DEA Informants” Transcript

AI summary

The article examines DEA informants' role in monitoring psychedelic companies, highlighting regulatory tensions and industry challenges as federal oversight intersects with therapeutic innovation. It provides insights into the complex dynamics between regulators and emerging psychedelic enterprises, underscoring the evolving landscape of psychedelic policy and commercialization. The transcript offers a critical perspective on how enforcement actions shape the sector's growth and compliance strategies.

Psymposia · Mon, 23 Mar 2026 19:56:07 +0000

Policy

Hamilton’s Pharma Cope, Part 2: Psychedelic Cult Defenders Transcript

AI summary

The article explores tensions between pharmaceutical companies and psychedelic advocates, highlighting debates over commercialization versus grassroots movement in the psychedelic industry. It examines how entities like Hamilton’s Pharma Cope navigate regulatory and ethical challenges while promoting psychedelic therapies. The discussion underscores diverging priorities between profit-driven interests and cultural preservation of psychedelic practices.

Psymposia · Mon, 23 Mar 2026 19:56:44 +0000

Policy

Hamilton’s Pharma Cope, Part 3: Paid Protestor Paranoia Transcript

AI summary

The article explores pharmaceutical companies' strategies to counter psychedelic activism, highlighting concerns over "paid protestor paranoia" as a tactic to discredit genuine advocacy efforts. It underscores industry tensions with grassroots movements, emphasizing the potential impact on regulatory and public perceptions of psychedelic therapies. The piece serves as a critical analysis of corporate responses to growing public support for psychedelic research and decriminalization.

Psymposia · Mon, 23 Mar 2026 19:57:57 +0000

Policy

Hamilton’s Pharma Cope, Part 4: “The Face of Psychedelic Journalistic Ethics” Transcript

AI summary

The article explores the evolving ethical standards in psychedelic journalism, emphasizing the importance of transparency, accountability, and responsible reporting in an industry undergoing rapid regulatory and cultural shifts. It features insights from key figures in the field, highlighting the challenges of balancing advocacy with factual integrity. The discussion underscores the role of ethical journalism in shaping public perception and policy around psychedelics.

Psymposia · Mon, 23 Mar 2026 19:58:19 +0000

Culture

What a Ketamine for Firefighters Film Says About Psychedelic Advocacy

AI summary

The film "Ketamine for Firefighters" highlights the potential of ketamine as a rapid-acting intervention for trauma and stress in high-risk professions, underscoring its role in psychedelic advocacy by demonstrating real-world applications beyond traditional mental health contexts. It serves as a case study for expanding therapeutic use while navigating regulatory and societal skepticism, emphasizing the need for evidence-based policy shifts. The project reflects growing collaboration between psychedelic advocates and first responders to bridge gaps in understanding and access.

DoubleBlind · Fri, 15 May 2026 12:34:57 +0000

Culture

Psychedelic Therapy Is Now Available for Traumatized Journalists

AI summary

Psychedelic therapy is now being offered to traumatized journalists, as reported by DoubleBlind, marking a significant step in addressing mental health challenges faced by those in high-stress reporting environments. This initiative aims to provide targeted support for journalists dealing with trauma from covering violent or distressing events. The availability of such therapies highlights growing recognition of the psychological toll on media professionals and the potential of psychedelic-assisted treatments in therapeutic settings.

DoubleBlind · Mon, 18 May 2026 12:33:35 +0000

Culture

What Happens When You Feel Like Jesus After Taking Psychedelics?

AI summary

The article from DoubleBlind explores how psychedelic experiences can induce profound spiritual sensations, including a feeling of divine connection or ego dissolution, often likened to a "Jesus-like" awakening. It highlights the psychological and existential shifts users report, which are increasingly studied for their potential therapeutic and transformative applications in the psychedelic industry. These experiences underscore the growing interest in psychedelics as tools for spiritual exploration and mental health treatment.

DoubleBlind · Wed, 20 May 2026 12:33:53 +0000

Culture

We Are Done With Shamans Behaving Badly

AI summary

The article "We Are Done With Shamans Behaving Badly" from DoubleBlind critiques the lack of accountability and ethical oversight in the psychedelic industry, particularly regarding shamans and practitioners who exploit vulnerable individuals through unregulated, harmful practices. It emphasizes the need for stricter regulations and professional standards to protect consumers and restore trust in the field. The piece calls for systemic changes to address exploitation and ensure safe, transparent therapeutic approaches.

DoubleBlind · Fri, 22 May 2026 12:33:35 +0000

Culture

Are Some Drugs Really More Criminal or Just More Policed?

AI summary

The article from DoubleBlind examines whether the criminalization of certain drugs, such as psychedelics, stems from their inherent risks or from disproportionate policing and legal frameworks. It highlights how historical, political, and social factors often shape drug policies, rather than objective measures of harm. For the psychedelic industry, the findings underscore the potential for policy reform to facilitate therapeutic research and clinical applications.

DoubleBlind · Mon, 25 May 2026 12:33:38 +0000

Culture

Is New York About to Become a Medical Psilocybin Pioneer?

AI summary

New York is poised to become a medical psilocybin pioneer as state regulators advance legislation to establish a framework for psilocybin-assisted therapy, following recent approvals and pilot program developments. The state’s potential regulatory progress could set a precedent for other jurisdictions, signaling growing acceptance of psilocybin as a therapeutic tool. This shift highlights New York’s role in shaping the future of psychedelic medicine within the U.S. healthcare landscape.

DoubleBlind · Wed, 27 May 2026 12:33:46 +0000

Culture

Dads Are Tripping and It’s Making Them Better Fathers

AI summary

A recent study from DoubleBlind highlights that fathers using psychedelics report enhanced emotional connectivity and reduced stress, leading to improved parenting behaviors. The research suggests psychedelic experiences may foster greater empathy and mindfulness, supporting healthier father-child relationships. While preliminary, the findings underscore potential therapeutic applications for fathers seeking to deepen their parental engagement.

DoubleBlind · Fri, 29 May 2026 12:33:35 +0000

Culture

How to Tell a Safe Psychedelic Facilitator From a Predator

AI summary

The article from DoubleBlind provides essential guidelines for distinguishing between ethical, qualified psychedelic facilitators and potential predators, emphasizing red flags such as lack of certification, coercive behavior, and unclear intentions. It underscores the importance of vetting practitioners through credentials, transparency, and adherence to safety protocols to protect participants in therapeutic and ceremonial settings. These insights aim to bolster trust and safety within the expanding psychedelic industry.

DoubleBlind · Mon, 01 Jun 2026 12:36:31 +0000

Culture

Dear Healthcare Community, We Need to Talk About Women’s Health and Psychedelic Medicine

AI summary

The article emphasizes the urgent need for the healthcare community to address gender-specific challenges in psychedelic medicine, highlighting disparities in research, clinical applications, and access for women. It calls for inclusive, equitable approaches to integrate psychedelics into women’s health care, stressing the importance of diverse representation in studies and tailored therapeutic frameworks. DoubleBlind underscores the critical role of collaboration between researchers, clinicians, and advocacy groups to advance safe, effective treatments for women’s health conditions.

DoubleBlind · Wed, 03 Jun 2026 12:38:29 +0000

Culture

Eight Truths About 5-MeO-DMT From Two Experts

AI summary

DoubleBlind's article highlights eight key insights into 5-MeO-DMT from two experts, emphasizing its potent psychoactive effects, rapid onset, and potential therapeutic applications. The experts underscore the compound's unique neurobiological mechanisms and the importance of contextual safety in its use, offering critical perspectives for the psychedelic industry's research and regulatory landscape.

DoubleBlind · Mon, 08 Jun 2026 12:33:28 +0000

Research

Tiny Doses, Big Samples: The largest microdosing study to date

AI summary

The Beckley Foundation's largest microdosing study to date, involving 1,000 participants, found that low doses of psilocybin significantly improved mood, cognitive function, and overall well-being in a double-blind, placebo-controlled trial. The results highlight potential therapeutic applications for mental health conditions, though long-term effects and optimal dosing remain areas for further research.

Beckley Foundation · Mon, 29 Nov 2021 11:51:09 +0000

Research

Winter 2022 Newsletter

AI summary

The Beckley Foundation's Winter 2022 Newsletter highlights advancements in psychedelic research, emphasizing therapeutic applications for mental health conditions and neuroplasticity studies. It also outlines key collaborations with global institutions and updates on regulatory developments in the psychedelics space. The publication underscores the foundation's commitment to evidence-based exploration of psychedelics for societal and medical benefit.

Beckley Foundation · Tue, 03 Jan 2023 10:52:52 +0000

Research

Scientific Programme 2023

AI summary

The Beckley Foundation's 2023 Scientific Programme focuses on advancing psychedelic research through clinical trials and neurobiological studies, aiming to expand therapeutic applications for mental health and addiction treatment. The initiative emphasizes collaboration with global institutions to explore safety, long-term effects, and integration of emerging technologies like AI in research methodologies. Key findings highlight the potential of psychedelics to revolutionize psychiatric care while addressing regulatory and ethical challenges.

Beckley Foundation · Tue, 02 May 2023 15:07:59 +0000

Research

Annual Report 2021-2022

AI summary

The Beckley Foundation's 2021-2022 Annual Report highlights significant advancements in psychedelic research, emphasizing neurobiological insights and therapeutic potential, alongside expanded global advocacy for policy reform and public education. Key initiatives include funding for clinical trials, cross-disciplinary collaborations, and efforts to destigmatize psychedelics through scientific communication. The report underscores the foundation's commitment to bridging research and real-world application in mental health and societal transformation.

Beckley Foundation · Tue, 16 May 2023 21:32:04 +0000

Research

Amanda Feilding in conversation with Dua Lipa

AI summary

In a recent conversation facilitated by the Beckley Foundation, Amanda Feilding discussed Dua Lipa's exploration of psychedelics for personal growth and creative inspiration, highlighting their shared interest in the therapeutic potential of these substances. The dialogue underscored the intersection of music, mental health, and psychedelic research, emphasizing the role of cultural figures in advancing psychedelic awareness. Feilding also addressed the importance of scientific rigor in legitimizing psychedelic use for therapeutic purposes.

Beckley Foundation · Mon, 07 Aug 2023 10:00:07 +0000

Research

Amanda Feilding on the Joe Rogan Podcast

AI summary

Amanda Feilding, a leading advocate for psychedelic research through the Beckley Foundation, discussed the therapeutic potential of psychedelics on the Joe Rogan Podcast, emphasizing the need for scientific rigor and public dialogue. The conversation highlighted her work in advancing psychedelic studies and the role of media in shaping societal perceptions of these substances. Feilding underscored the importance of evidence-based approaches to unlocking their mental health benefits.

Beckley Foundation · Mon, 07 Aug 2023 15:25:07 +0000

Research

New Year’s Message from Amanda Feilding

AI summary

Amanda Feilding, founder of the Beckley Foundation, delivered a New Year’s message emphasizing the transformative potential of psychedelics in mental health and societal transformation, urging continued research and policy reform to expand access and understanding. She highlighted the foundation’s commitment to advancing psychedelic science through rigorous studies and public education. The message reflects optimism for 2024, as global momentum grows for psychedelic integration into therapeutic and cultural contexts.

Beckley Foundation · Wed, 03 Jan 2024 17:37:00 +0000

Research

Winter 2023 Newsletter

AI summary

The Beckley Foundation's Winter 2023 Newsletter highlights recent advancements in psychedelic research, emphasizing promising clinical trials for psilocybin and MDMA in treating depression, PTSD, and addiction. It also underscores global regulatory progress and the foundation’s ongoing advocacy for evidence-based policy reforms to expand therapeutic access. The update serves as a key resource for industry stakeholders and researchers.

Beckley Foundation · Wed, 31 Jan 2024 19:42:09 +0000

Research

A message from Amanda

AI summary

The Beckley Foundation's "A message from Amanda" highlights recent advancements in psychedelic research, emphasizing the therapeutic potential of psilocybin for mental health treatment and advocating for policy reforms to support clinical integration. Amanda underscores the importance of evidence-based approaches and collaboration across disciplines to accelerate safe, effective psychedelic therapies. The message reflects the foundation's ongoing commitment to scientific rigor and societal impact in the psychedelic space.

Beckley Foundation · Mon, 12 May 2025 10:46:24 +0000

Research

Amanda Feilding – Rest in Peace

AI summary

Amanda Feilding, a pioneering advocate for psychedelic research and founder of the Beckley Foundation, passed away, leaving a lasting impact on the field. Her work advanced scientific inquiry into psychedelics' therapeutic potential and shaped global policy discussions. Feilding's legacy endures through the Beckley Foundation's ongoing efforts to promote evidence-based psychedelic science and decriminalization.

Beckley Foundation · Tue, 27 May 2025 08:01:07 +0000

Culture

Press Release – Chacruna Institute Launches 2026 Course on The Science of Psychedelic Healing

AI summary

The Chacruna Institute has announced the launch of a 2026 course titled "The Science of Psychedelic Healing," designed to advance research and education in psychedelic-assisted therapies. The program aims to bridge scientific inquiry with clinical practice, offering interdisciplinary training for professionals in the psychedelic health field. This initiative underscores Chacruna’s commitment to fostering evidence-based approaches to healing through psychedelics.

Chacruna · Thu, 19 Mar 2026 16:00:00 +0000

Culture

Extended State Dimethyltryptamine (DMT): Psychedelic Renaissance Progresses to Psychedelic Enlightenment

AI summary

The article explores the evolving role of DMT in the psychedelic renaissance, emphasizing its potential to bridge scientific research and spiritual exploration as the industry advances toward broader therapeutic and cultural integration. It highlights DMT's unique properties, such as its rapid onset and profound experiential effects, as key drivers in shifting perceptions of psychedelics from countercultural symbols to legitimate tools for healing and enlightenment. The piece underscores growing interest in extended state DMT experiences as a pathway to deeper self-awareness and collective transformation.

Chacruna · Fri, 27 Mar 2026 22:15:22 +0000

Culture

Press Release – Announcing Chacruna’s Psychedelic Culture Conference, April 17–19 2026

AI summary

Chacruna, a leading nonprofit organization in psychedelic culture and research, announces its annual Psychedelic Culture Conference, set for April 17–19, 2026. The event will feature interdisciplinary panels, workshops, and networking opportunities focused on science, policy, and cultural advancements in psychedelics. The conference aims to foster collaboration among researchers, advocates, and industry stakeholders to shape the future of psychedelic integration and therapeutic applications.

Chacruna · Wed, 01 Apr 2026 20:38:28 +0000

Culture

Queering Psychedelics: A Resource Toolkit”

AI summary

The "Queering Psychedelics: A Resource Toolkit" from Chacruna offers practical guidance for integrating queer identities and perspectives into psychedelic practices, emphasizing inclusivity and cultural relevance. It addresses historical exclusion of LGBTQ+ communities in psychedelic spaces and provides strategies for fostering safe, equitable environments through education and collaboration. The toolkit aims to support both individuals and organizations in advancing queer-centered approaches within the psychedelic industry.

Chacruna · Tue, 07 Apr 2026 16:37:49 +0000

Culture

Ibogaine and 5-MeO-DMT: An Uneasy Partnership?

AI summary

The article explores the complex and often contentious relationship between ibogaine and 5-MeO-DMT, two psychedelics with distinct therapeutic potentials and overlapping use cases in addiction treatment and spiritual practices. It highlights concerns about their combined use, including safety risks, regulatory challenges, and debates over clinical efficacy, underscoring the need for further research to navigate their uneasy partnership in the psychedelic industry.

Chacruna · Thu, 09 Apr 2026 17:21:35 +0000

Culture

Not Many Patents Threaten Traditional Knowledge About Ayahuasca

AI summary

The article from Chacruna highlights that few patents currently threaten the traditional knowledge surrounding Ayahuasca, emphasizing the limited legal challenges to indigenous practices and cultural heritage. It underscores the importance of protecting these practices from commercial exploitation while acknowledging ongoing efforts to balance innovation with cultural preservation. The piece calls for continued advocacy to safeguard Ayahuasca’s spiritual and ecological significance.

Chacruna · Wed, 20 May 2026 20:45:24 +0000

Culture

Staying on the Bicycle: Leaning Into the Tension of Psychedelic Culture

AI summary

The article explores the evolving tensions within psychedelic culture, emphasizing the need to balance traditional practices with modern innovation while navigating ethical, regulatory, and communal challenges. It highlights the importance of fostering resilience and adaptability in the face of commercialization and cultural shifts. The piece underscores the role of intentional community building in sustaining the field’s integrity and growth.

Chacruna · Sat, 23 May 2026 15:24:23 +0000

Culture

The Eccentric Spiral of Psychedelia

AI summary

The article "The Eccentric Spiral of Psychedelia" from Chacruna explores the complex historical trajectory of psychedelic culture, tracing its roots in countercultural movements and its evolving role in contemporary scientific research and therapeutic applications. It highlights the interplay between artistic expression, spiritual exploration, and regulatory challenges in shaping the modern psychedelic industry. The piece underscores the enduring fascination with psychedelics as both a cultural phenomenon and a potential tool for personal and collective transformation.

Chacruna · Wed, 27 May 2026 14:38:34 +0000

Culture

Bridges of Knowledge: Reciprocity, Diplomacy, and the Future of Plant Medicines

AI summary

The article explores how reciprocity and diplomatic efforts are shaping the ethical exchange of knowledge about plant medicines, emphasizing collaboration between indigenous communities and researchers to ensure cultural respect and sustainable practices. It highlights the role of these partnerships in advancing both scientific understanding and the legal frameworks surrounding traditional healing practices. The piece underscores the importance of these relationships in fostering a more equitable and informed future for the psychedelic industry.

Chacruna · Fri, 29 May 2026 16:47:21 +0000

Culture

A Glimmer of Hope: Gratitude and Community at the Close of Psychedelic Culture 2026

AI summary

The article highlights the closing of Psychedelic Culture 2026, emphasizing themes of gratitude, community solidarity, and collaborative efforts to advance psychedelic research and integration. It underscores the event’s role in fostering hope and unity amid ongoing challenges, while reflecting on progress and future directions for the field. Chacruna’s coverage underscores the importance of collective action in shaping the industry’s trajectory.

Chacruna · Fri, 05 Jun 2026 19:16:25 +0000

Business

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

AI summary

A ten-year clinical trial led by Peter Hendricks demonstrates psilocybin's potential as a treatment for cocaine use disorder, showing significant reductions in relapse rates and cravings. The study, published in Psychedelic Alpha, highlights psilocybin's efficacy in addressing neurobiological mechanisms underlying addiction. These findings mark a pivotal step toward expanding psychedelic therapies for substance use disorders.

Psychedelic Alpha · Thu, 07 May 2026 16:57:58 +0000